74 results about "Granuloma" patented technology

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The invention provides a water-in-oil adjuvant for animal vaccines and a preparation method and application thereof, and relates to the technical field of biology, the water-in-oil adjuvant comprises 73%-75% of oil for injection, 20%-23% of an emulsifier and 2%-7% of a stabilizer; the emulsifying agent is prepared from 4.5 percent to 5 percent of polyoxyethylene fatty alcohol ether, 3.0 percent to 3.5 percent of glycerol monoisostearate, 7.0 percent to 8.0 percent of span 80, 4.5 percent to 5 percent of Tween 80 and 1 percent to 1.5 percent of vitamin E; the vaccine prepared from the water-in-oil adjuvant has the advantages that the viscosity is reduced, and the injection is easy. The technical problems that in the prior art, a vaccine prepared from an oil-in-water adjuvant is large in viscosity, so that resistance is large during injection, the occurrence rate of side reactions is high, an injection part swells, and granuloma is formed are solved.

The invention discloses injectable poly-L-lactic acid microsphere composite gel capable of inducing rapid regeneration and instant filling of collagen, which is characterized in that poly-L-lactic acid is used as a raw material, and poly-L-lactic acid microspheres are prepared by adopting an emulsification method; the preparation method comprises the following steps: taking collagen and oxidized polysaccharide as raw materials, carrying out Schiff alkali cross-linking reaction on the collagen and the oxidized polysaccharide to prepare composite gel, and uniformly distributing L-polylactic acid microspheres in the composite gel. The aldehyde group on the oxidized polysaccharide and the amino group on the collagen are subjected to a Schiff base cross-linking reaction to form the injectable gel with a three-dimensional network structure. The cross-linked gel provides mechanical tension to uniformly disperse the PLLA microspheres, so that the microspheres are prevented from settling or agglomerating. The composite gel can also improve the hydrophilicity of the microspheres, so that the redissolution dispersity of the microsphere filler is better, and the microspheres settle more slowly. After being injected subcutaneously, the collagen gel can be instantly filled and induce rapid regeneration of collagen, has no chemical cross-linking agent residue, and reduces the risk of inflammation (such as granuloma) caused by the organism and the like.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to a water-in-oil-in-water adjuvant, a veterinary vaccine and a preparation method thereof.The water-in-oil-in-water adjuvant is prepared from, by weight, 0.5%-7.5% of a hydrophilic composite surfactant, 0.6%-9.8% of an oleophylic composite surfactant, 70%-85% of mineral oil and the balance water; and the mineral oil also comprises the following components in concentration: a reinforcing agent of 0.45-0.9 g / ml and a stabilizing agent of 2-6.9 g / L, wherein the water-in-oil-in-water adjuvant forms a gelatinous structure under the regulation of the stabilizer and is a non-Newtonian fluid of which the viscosity is not higher than 25cp; the adjuvant shows the non-flowing fluid characteristic through the stabilizer, the rheological property of the produced vaccine is enhanced, the stability of the vaccine is improved, on the premise that the hydrophilic surfactant and the oleophylic surfactant are balanced, the natural polymer enhancer is added, and on the premise that the adjuvant viscosity is reduced and granuloma side reaction is not prone to being generated, the stability of the vaccine is improved. Short-term immunity and long-term immunity can be induced at the same time, and the application of the water-in-oil-in-water adjuvant in the field of veterinary vaccines is expanded.

The present invention relates to anti-CD 103 antibodies, as well as use of these antibodies in diagnosis, prognosis, monitoring, and treatment of diseases. Also disclosed is an imaging agent comprising the anti-CD 103 antibody and a detectable label, wherein the antibody either does not block CD 103 binding to E-cadherin or at least partially blocks CD 103 binding to E-cadherin. The methods of treatment involve administering the anti CD 103 antibody which may be optionally coupled to a cytotoxic agent. Diseases to be treated include e.g. Hairy Cell leukemia, HCLv, intestinal and extraintestinal lymphomas, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Sezary Syndrome (SS), Alzheimer's disease, Parkinson's disease or multiple sclerosis.

The application relates to a method for identifying granulomatous mastitis and non-mass-like enhancement breast cancer, which comprises the following steps: reading original data of a peak enhancement period of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) collected by a magnetic resonance device, segmenting and labeling a lesion area to obtain a segmentation mask; pre-processing the DCE-MRI image and generating three-slice samples, including spatial resampling, intensity normalization, lesion centering and cutting, continuous three-slice sampling and mask superposition fusion; dividing the data into a training set and a test set according to the patient level, and adopting stratified sampling to maintain category balance; constructing a double-attention classification model based on DenseNet121, integrating a convolution block attention module (CBAM) and a selective kernel network module (SKNet) by adopting a progressive insertion strategy; training the model and testing by adopting a lesion-level voting strategy to obtain the identification result of the granulomatous mastitis and the non-mass-like enhancement breast cancer. The method solves the problem that the deep learning research on the identification of GM and NMEBC on the DCE-MRI is insufficient, and has high classification precision and good calibration.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.

The present invention discloses a computer device and computer-readable storage medium for identifying or assisting in the identification of large cell transformation of mycosis fungoides. The present invention provides a computer device comprising a memory, a processor, and a computer program stored in the memory, wherein the processor performs the following steps: S1) data reception: receiving the percentage of FOXM1-positive cells in skin lesions of a subject with mycosis fungoides (MF); S2) data output: outputting result information from the computer based on the percentage of FOXM1-positive cells, wherein the result information indicates whether the subject with mycosis fungoides has, or is a candidate for, large cell transformation of mycosis fungoides. Experiments in the present invention demonstrate that immunohistochemical staining for FOXM1 can more accurately locate large cells and quantify the proportion of large cells compared to traditional pathological techniques, thereby reducing subjective bias. Therefore, it is proposed that immunohistochemical staining for FOXM1 can be used as an auxiliary technique for diagnosing large cell transformation of mycosis fungoides.

The present invention provides an antibody or a conjugated fragment of a citrulline-containing epitope used for the treatment or prevention of diseases associated with the release of extracellular traps from cells, such as neutrophil extracellular trap (NET)-associated pathology (NET-associated pathology) or eosinophil extracellular trap (EET)-associated pathology (EET-associated pathology), and provides a method comprising administering at least one dose of the antibody at a specific concentration. The present invention also provides the method itself. NET-related pathologies include systemic lupus erythematosus (SLE), lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus exacerbated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, or wound healing in diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in This includes other NET-related pathologies, such as the health of transplanted organs in vivo or ex vivo.The present invention also relates to wound healing in SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), Sjögren's disease, antiphospholipid antibody syndrome, Behçet's disease, spondylitis, spondyloarthritis, multiple system atrophy, Parkinson's disease, Lewy body dementia asthma, allergic rhinovirus exacerbating asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulomatous uveitis, granulomatous uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, or diabetes, cancer, cancer metastasis, or wound healing in diabetes, cancer, cancer metastasis, and in vivo or ex vivo The present invention provides pharmaceutical compositions and methods for treating and preventing NET-related pathologies, including other NET-related pathologies such as the health of transplanted organs in vivo. NET-related pathologies include eosinophilic diseases or conditions of the skin, respiratory eosinophilic diseases or conditions, gastrointestinal eosinophilic diseases or conditions, allergic diseases or conditions, or eosinophilic diseases or conditions such as helminthic, fungal, viral or bacterial infections.

The application discloses a kind of treatment granulomatous lobular mastitis plaster and preparation method thereof, it is related to traditional Chinese medicine technical field, and its technical solution points are: rhubarb, golden poplar, radix scutellariae, sanguisorba officinalis, gardenia, turmeric, purple grass, water decoct 2 times, first time 9-11 times water amount of medicinal materials is added, decoct 1-3 hours, second time 6-9 times water amount of medicinal materials is added, decoct 1-2 hours, two water decocting liquids are combined, after filtration, concentrate and obtain ointment, carry out coating, cut according to specification and place to make it solidification and shape.The application can realize the treatment granulomatous lobular mastitis, can reduce mastitis inflammation index score and inflammatory cell infiltration degree, by reducing the expression of IL6, CD86, TYROBP, ITGAX and regulating related path, play the role of treatment granulomatous lobular mastitis.

The present invention provides an antibody comprising citrulline epitope or a binding fragment thereof for use in the treatment or prevention of a disease associated with release of an extracellular trap from a cell, such as a neutrophil extracellular trap (NET)-associated disease (NET-associated disease) or an eosinophil extracellular trap (EET)-associated disease (EET-associated disease), the method comprises administering at least one dose of an antibody at a specific concentration. The present invention also provides these methods themselves. NET related diseases include systemic lupus erythematosus (SLE), lupus, septicemia, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, and the like. Parkinson's disease, Lewy body dementia, asthma, allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulogenic uveitis, granulogenic uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The invention also provides a pharmaceutical composition and a method for treating or preventing NET related diseases. Such as SLE, lupus, sepsis, vasculitis, inflammatory arthritis, rheumatoid arthritis and osteoarthritis, psoriasis, Alzheimer's disease, autoimmune hepatitis, juvenile idiopathic arthritis, myositis (polymyositis and dermatomyositis), sicca syndrome, antiphospholipid syndrome, Behcet's disease, spondylitis, spondyloarthropathy, multi-system atrophy, Parkinson's disease, Lewy body dementia, asthma, and the like. Allergic rhinovirus aggravated asthma, allergic asthma, acute respiratory distress syndrome, cystic fibrosis, fibrosis and idiopathic pulmonary fibrosis, heart failure, atherosclerosis, dry eye disease, uveitis, non-granulometric uveitis, granulometric uveitis, dermatitis, atopic dermatitis, COPD, bronchitis, thrombotic disease, cardiovascular disease, and the like. Or other NET-related diseases, such as wound healing in diabetic patients, cancer, cancer metastasis, and transplanted organ health in vivo or in vitro. The EET-related diseases include eosinophilic granulocyte diseases or conditions, such as eosinophilic granulocyte diseases or conditions of skin; a respiratory eosinophilic granulocyte disease or condition; gastrointestinal eosinophilic cell diseases or disorders; allergic diseases or conditions; or worm, fungus, virus or bacterial infection.

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof. In some embodiments, an outcome of the methods of the present technology is increased relative to the same method comprising use of a corticosteroid.

This disclosure provides antibodies that specifically bind to human PAR-2, antigen-binding fragments thereof, and compositions comprising such antibodies or antigen-binding fragments thereof. [Solution] In certain embodiments, an antibody or antigen-binding fragment thereof that specifically binds to human PAR-2 ​​blocks the interaction between the PAR-2 ​​activating ligand and the extracellular domain of PAR-2, and / or blocks PAR-2 ​​activation by the PAR-2 ​​activating ligand. In further embodiments, the antibody or antigen-binding fragment can be used to treat diseases or conditions associated with increased PAR-2 ​​expression, and / or diseases or conditions that can be alleviated by antagonizing the activation of PAR-2 ​​by the PAR-2 ​​activating ligand (e.g., respiratory diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

To provide a pharmaceutical composition for treating lung inflammation in a mammalian subject having a granulomatous pulmonary disease.SOLUTION: A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a GHRH antagonist.SELECTED DRAWING: None

The present disclosure relates to crystalline forms of N-(l-(tert-butyl)-lH-pyrazol-4-yl)-2-( 4-((6-((methylsulfonyl)quinolin-4-yl)oxy)-3-methylphenyl)acetamide of formula (II) and crystalline forms of salts thereof. The compound of formula (II) is a RIPK2 inhibitor for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and more specifically for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease

The application discloses a chrysanthemum stem and leaf active extract with improved fish heavy metal poisoning and a preparation method thereof. The chrysanthemum stem and leaf active extract is compounded by a chrysanthemum stem and leaf crude polysaccharide part and a chrysanthemum stem and leaf phenolic ketone part. The pharmacodynamic experiment results show that the chrysanthemum stem and leaf active extract has a good improvement effect on fish heavy metal poisoning. The chrysanthemum stem and leaf active extract can not only improve pathological changes such as heart and liver granuloma, kidney tubular cast, intestinal cavity expansion and gill lamella shedding caused by heavy metal poisoning, but also improve metabolic dysfunction such as taurine and hypotaurine metabolic disorder, pyruvic acid metabolic abnormality, tricarboxylic acid cycle disorder, glycolysis and gluconeogenesis disorder caused by heavy metal poisoning. The preparation method has reasonable whole preparation process design, can realize waste utilization, extends a chrysanthemum industry chain, expands a chrysanthemum resource utilization approach, is helpful to quality improvement and efficiency increase and green development of the chrysanthemum industry, and provides support for prevention and treatment of heavy metal poisoning.

The invention belongs to the field of animal models, particularly relates to a granulomatous mastitis animal model and a construction method thereof, and aims to solve the problems of low pathological matching degree and poor repeatability of an existing model. The construction method comprises the following steps: selecting an SPF-grade BALB / c female mouse (10 weeks old, 20-22 g), preparing human mammary gland fresh lesion tissue homogenate and lesion origin staphylococcus aureus liquid (1.4 * 10 < 8 >-1.5 * 10 < 8 > CFU / mL), mixing and emulsifying with a Freund's incomplete adjuvant according to a ratio of 1: 1: 1, injecting to the third pair of mammary glands of the mouse, and completing modeling in two weeks. The pathological characteristics of the model are highly matched with human diseases, the success rate is high, the repeatability is strong, and the model can be used for GM pathogenesis research and therapeutic drug screening.

A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG / Il2rg KO / hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer.

The invention provides application of forsythin and / or derivatives, solvates, hydrates or pharmaceutically acceptable salts thereof in preparation of drugs for treating and / or preventing pulmonary nodules. The medicine disclosed by the invention can be used for remarkably inhibiting the granuloma area of mice with pulmonary nodules and reducing the levels of inflammatory factors and chemotactic factors. Compared with a fructus forsythiae extract, forsythin shows a better anti-pulmonary nodule effect and has a better application prospect.

The present application relates to the technical field of biomedical materials, and particularly relates to porous hydroxyapatite particles, a preparation method and application thereof, which comprises the following steps: step S1, crosslinking a crosslinking agent and a macromolecular polymer to obtain a polymer gel; step S2, granulating the polymer gel to obtain gel particles; step S3, soaking the gel particles in a calcium ion solution, washing thoroughly, then soaking in a phosphate solution, washing thoroughly, repeating the foregoing operation for several times to mineralize, and obtaining mineralized gel particles; and step S4, calcining the mineralized gel particles in a muffle furnace at high temperature to obtain porous hydroxyapatite particles; the present application carries out biomimetic mineralization by using a polymer gel as a template, and the pore density can be determined according to the crosslinking degree of the polymer gel, so that the degradation environment can be effectively adapted to realize rapid and safe degradation, and no adverse reactions such as granuloma and hard nodules are caused.

To provide a novel agent for treating eosinophilic granulomatosis with polyangiitis (EGPA). [Solution] A treatment agent for EGPA comprising methyl (1-{[6-{[(1S)-1-cyclopropylethyl]amino}-2-(pyrazolo[5,1-b][1,3]thiazol-7-yl)pyrimidin-4-yl]carbonyl}piperidin-4-yl)carbamate, its pharmaceutically acceptable salt, or its hydrate.

Sarcoidosis is a multisystem disease characterized by granulomatous inflammation in affected organs. The present invention discloses kits and a system for a blood test using mycobacterial catalase-peroxidase that has a high positive predictive value for confirming a diagnosis of sarcoidosis.

The application discloses a granuloma circular representation positioning method and system based on multi-scale feature aggregation, first, collecting a histopathological image; then, performing preliminary feature encoding and extraction through a Patch Embedding module of a detection network; then, obtaining multi-scale aggregation feature output through a plurality of multi-scale attention feature extraction stages of the detection network; further, performing different scale feature fusion from top to bottom on the output features of each feature extraction stage through a feature fusion module FPN of the detection network; finally, positioning and detecting the granuloma in the histopathological image through three detection heads of the detection network; the application uses a Transformer structure based on multi-scale feature aggregation to extract image features, so that effective learning of a plurality of different scale features is realized, and the effect that both large targets and small targets can be effectively detected is achieved.

The invention relates to application of aspirin in preparation of an anti-schistosoma japonicum medicine, and in the invention, by applying a schistosoma japonicum infection mouse model, the treatment effect of aspirin on schistosoma japonicum is found. Specifically, the aspirin can significantly reduce the number of insect bodies infected in mice and the number of eggs deposited in livers, and can effectively inhibit the antigen secretion ability of the eggs infected in the livers of the mice, the granuloma inflammation induced by the eggs and the hepatic fibrosis degree, so that the aspirin can be applied to treatment of schistosoma japonicum katsurada. And a new application of aspirin is added clinically. As a non-steroidal anti-inflammatory drug, aspirin is widely applied clinically, has the advantages of safety, reliability, stability, low cost, easiness in obtaining and the like, and is relatively deep in pharmacological research and relatively clear in action mechanism. Therefore, the scheme of the invention is suitable for clinical popularization and use.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I):The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease and cancer.

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and / or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and / or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

Among other things, the present disclosure provides adenoviral vectors, genomes, and methods of use thereof. In some embodiments, the present disclosure provides methods of in vivo gene therapy comprising administration of an adenoviral payload vector and an adenoviral integration vector. The present disclosure provides, among other things, compositions comprising an adenoviral payload vector and an adenoviral integration vector for use in, e.g., methods of in vivo gene therapy. In some embodiments, the present disclosure provides adenoviral vectors, genomes, and compositions thereof comprising a therapeutic sequence, e.g., a nucleic acid sequence encoding a CYBB therapeutic polypeptide. In some embodiments, the present disclosure provides methods of treating various conditions, disorders, and diseases, e.g., chronic granulomatous disease.

The present invention relates to hydrogen sulfide (H2S) releaser compounds and compositions for use in the treatment of myeloperoxidase (MPO) induced neutrophil mediated tissue damage, in particular positive anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV), comprising myeloperoxidase granulomatous polyvasculitis (Wegner's granulomatous disease), eosinophilic granulomatous polyvasculitis (EGPA; ), polyvasculitis under microscope (MPA), and various forms of diseases in various organs, such as kidney and lung.

The application discloses a kind of external use traditional Chinese medicine preparation for treating cold blood stasis type granulomatous lobular mastitis and preparation method, and external use traditional Chinese medicine preparation is made of the raw materials including the following medicinal materials: prepared rhizome of rehmannia, antler slice, cassia, gunpowder ginger, chuanxiong, safflower, golden cypress, radix angelicae pubescentis, spironolactone, white and so on.The external preparation formula of the application is warm and blood tonic, blood-activating and skin-regenerating, has better clinical effect of treating cold blood stasis type granulomatous lobular mastitis, can effectively reduce the size of mass in clinical test, improve patient life treatment score, reduce the pain of patient, and has greater popularization and application value.